-
April 16, 2019PREVIEW
Use of apixaban (Eliquis—Bristol-Myers Squibb, Pfizer) as thromboprophylaxis in intermediate- to high-risk ambulatory patients receiving chemotherapy for various types of cancers reduced the risk...
-
February 11, 2019PREVIEW
Use of apixaban (Eliquis—Bristol–Myers Squibb, Pfizer) appears to be more effective than rivaroxaban (Xarelto—Janssen) for prevention of recurrent venous thromboembolism (VTE) with a decreased...
-
January 22, 2019PREVIEW
In November 2018, the American Society of Hematology (ASH) released 6 of 10 chapters that summarize clinical practice guidelines on management of venous thromboembolism (VTE). One guideline...
-
December 11, 2018PREVIEW
Use of aspirin prophylaxis for patients undergoing a total knee arthroplasty (TKA) to prevent venous thromboembolism (VTE) was noninferior to other anticoagulant chemoprophylactic regimens....
-
September 11, 2018PREVIEW
Use of standard-dose apixaban (Eliquis—Bristol-Myers Squibb, Pfizer) in patients with atrial fibrillation (AF) and end-stage renal disease (ESRD) who are on dialysis was associated with a...
Pages
